Data & Images
|Product Name||Anti-TRIF Antibody|
|Description||Rabbit IgG polyclonal antibody for TIR domain-containing adapter molecule 1(TICAM1) detection. Tested with WB, IHC-P, IHC-F in Human.|
|Cite This Product||Anti-TRIF Antibody (Boster Biological Technology, Pleasanton CA, USA, Catalog # PA1902)|
|Replacement Item||This antibody may replace the following items: sc-130621|sc-27478|sc-514384 from Santa Cruz Biotechnology.|
*Our Boster Guarantee covers the use of this product in the above tested applications.
**For positive and negative control design, consult "Tissue specificity" under Protein Target Info.
|Recommended Detection Systems||Boster recommends Enhanced Chemiluminescent Kit with anti-Rabbit IgG (EK1002) for Western blot, and HRP Conjugated anti-Rabbit IgG Super Vision Assay Kit (SV0002-1) for IHC(P) and IHC(F).
*Blocking peptide can be purchased at $50. Contact us for more information
**Boster also offers various secondary antibodies for Immunoflourescecne and IHC. Take advantage of the buy 1 primary antibody get 1 secondary antibody for free promotion for the entire year 2018!
|Immunogen||A synthetic peptide corresponding to a sequence at the C-terminus of human TRIF(692-712aa NNHMWNQRGSQAPEDKTQEAE).|
|Cross Reactivity||No cross reactivity with other proteins|
|Contents||Each vial contains 5mg BSA, 0.9mg NaCl, 0.2mg Na2HPO4, 0.05mg Thimerosal, 0.05mg NaN3.|
|Concentration||Add 0.2ml of distilled water will yield a concentration of 500ug/ml.|
|Storage||At -20°C for one year. After reconstitution, at 4°C for one month. It can also be aliquotted and stored frozen at -20°C for a longer time.Avoid repeated freezing and thawing.|
|Purification||Immunogen affinity purified.|
Protein Target Info (Source: Uniprot.org)
You can check the tissue specificity below for information on selecting positive and negative control.
|Protein Name||TIR domain-containing adapter molecule 1|
|Molecular Weight||76422 MW|
|Protein Function||Involved in innate immunity against invading pathogens. Adapter used by TLR3 and TLR4 (through TICAM2) to mediate NF- kappa-B and interferon-regulatory factor (IRF) activation, and to induce apoptosis. Ligand binding to these receptors results in TRIF recruitment through its TIR domain. Distinct protein- interaction motifs allow recruitment of the effector proteins TBK1, TRAF6 and RIPK1, which in turn, lead to the activation of transcription factors IRF3 and IRF7, NF-kappa-B and FADD respectively. .|
|Tissue Specificity||Ubiquitously expressed but with higher levels in liver. .|
|Sequence Similarities||Contains 1 TIR domain.|
|Subcellular Localization||Cytoplasmic vesicle, autophagosome . Colocalizes with UBQLN1 in the autophagosome. .|
|Alternative Names||TIR domain-containing adapter molecule 1;TICAM-1;Proline-rich, vinculin and TIR domain-containing protein B;Putative NF-kappa-B-activating protein 502H;Toll-interleukin-1 receptor domain-containing adapter protein inducing interferon beta;MyD88-3;TIR domain-containing adapter protein inducing IFN-beta;TICAM1;PRVTIRB, TRIF;|
|Research Areas|||immunology|innate immunity|cytokines|interferons| immunology|tlr signaling||
Background for TIR domain-containing adapter molecule 1
Dilution Ratios/Recommended Concentrations
At Boster we strive to provide the best Anti-TRIF Antibody by testing all applications on non-spiked tissues and cell lines to ensure that the affinity of the antibody is enough to react to the endogenouse level of the target protein. Read more about our QC panel here.
|Recommended dilution ratios are listed below:|
Immunohistochemistry(Frozen Section), 0.5-1μg/ml, Human, -|
Immunohistochemistry(Paraffin-embedded Section), 0.5-1μg/ml, Human, By Heat
Western blot, 0.1-0.5μg/ml, Human
**Boster provides high sensitivity secondary antibody kits for Western blotting and IHC. For more info see Related Products below.
Anti-TRIF Antibody Images
Click the images to enlarge.
Recombinant Protein Detection Source: E.coli derived -recombinant Human TICAM1, 44.7KD (162aa tag+ Q468-E712)
Lane 1: Recombinant Human TICAM1 Protein 10ng
Lane 2: Recombinant Human TICAM1 Protein 5ng
Lane 3: Recombinant Human TICAM1 Protein 2.5ng
Lane 4: Recombinant Human TICAM1 Protein 1.25ng
Lane 1: JURKAT Cell Lysate
Lane 2: HL-60 Cell Lysate
IHC(P): Human Mammary Cancer Tissue
1. Post-translational modification:phosphorylation, methylation, glycosylation etc. These modifications prevent SDS molecules from binding to the target protein and thus make the band size appear larger than expected
2. Post-translational cleavage: this can cause smaller bands and or multiple bands
3. Alternative splicing: the same gene can have alternative splicing patterns generating different size proteins, all with reactivities to the antibody.
4. Amino Acid R chain charge: SDS binds to positive charges. The different size and charge of the Amino Acid side chains can affect the amount of SDS binding and thus affect the observed band size.
5. Multimers: Multimers are usually broken up in reducing conditions. However if the interactions between the multimers are strong, the band may appear higher.,